Drug profile · INN
daratumumab
DARZALEX
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
daratumumab (DARZALEX) is an FDA-listed pharmaceutical active ingredient. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN daratumumab
Brand DARZALEX
Route INJECTION
Formulation INJECTABLE
ATC code L01FC01
Originator Janssen-Cilag Pty Ltd
Frequently asked questions
What is daratumumab?
daratumumab (DARZALEX) is an FDA-listed pharmaceutical active ingredient. Associated with Janssen-Cilag Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daratumumab?
DARZALEX is a marketed brand name for daratumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daratumumab?
daratumumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.